ES Cell International Pte Ltd. develops human embroyonic stem cell technologies for research and commercial applications. It develops an array of intellectual property in the fields of drug discovery, diagnostics, and therapeutics based on stem cell technology. The company was founded by Ariff Bongso, Robert Klupacs, Martin F. Pera, Reubinoff Benjamin and Alan Osborne Trounson in 2000 and is headquartered in Singapore.

Lpath, Inc. is the category leader in the discovery and development of monoclonal antibodies that target (neutralize) bioactive lipids. The study of lipids (called lipidomics) is an emerging field of research that has already identified dozens of bioactive lipids that contribute to disease, with the promise of hundreds more as funding in the area continues to accelerate. Once a disease-causing lipid is identified, however, the challenge becomes one of generating a compound that neutralizes the relevant bioactive lipid. With its ImmuneY2:tm: platform technology and robust patent estate, Lpath is uniquely positioned to meet such challenges and exploit these opportunities.

International Stem Cell Corp. operates as a clinical stage biotechnology company. The firm engages in the development of therapeutic and biomedical products. It operates through the following segments: Cosmetic Market, Biomedical Market and Therapeutic Market. The Cosmetic Market segment develops, manufactures and markets cosmetic skin care products based on the company's proprietary parthenogenetic stem cell technology and targeted small molecule technology. The Biomedical Market segment is involved in the development, manufacture and commercialization of primary human cell research products. The Therapeutic Market segment focuses on the research and development of human parthenogenetic stem cells for the treatment of diseases of the central nervous system, liver diseases and is currently conducting clinical trials for the treatment of Parkinson's disease. The company was founded by William B. Adams, Kenneth C. Aldrich and Gregory S. Keller in June 2005 and is headquartered in San Diego, CA.

Kangstem Biotech develops technology to isolate the non-hematological system stem cell with conversion and purity from the cord blood and to culture large quantity. Its Furestem therapies include Furestem-AD, Furestem-RA and Furestem-CD. Its businesses include cord blood-derived stem cell therapy business; cord blood-derived stem cell conditioned media business; and stem cell culture media business.

At the beginning of the twentieth century, tuberculosis was one of the UK’s most urgent health problems. A royal commission, entitled The Royal Commission Appointed to Inquire into the Relations of Human and Animal Tuberculosis, was set up in 1901. It aimed to find out whether tuberculosis in animals and humans was the same disease and whether animals and humans could infect each other. This page describes how, by 1919, the Commission had evolved into the independent Medical Research Council.

Regen Biotech Co., Ltd. is a private company headquartered in the South Korea. The firm engages in biotechnology company.

Layton BioScience

Ichimaru Pharcos Co. Ltd. is a Japanese private company. The firm specializes in research and development, manufacturing and selling of raw materials for cosmetics, health foods and quasi drugs.

Leibniz Institute for Polymer Research Dresden provides research and analysis services by incorporating state-of-the-art technology.

NatureWise Biotech & Medicals Corp. engages in the wholesale and retail of Chinese and Western medicines and medical equipment. Its business includes retailing of category B patent medicine, food and beverage; and biotechnology service industry. Its products and services include new drug development, antitumor drugs, and retinopathy drugs. It specializes in Taiwanese Green Propolis Series and Red Yeast Rice Series. The company was founded on December 29, 2000 and is headquartered in Taipei, Taiwan.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Medipost Co., Ltd. engages in the development and manufacture of stem cell biotechnology products. It operates through the following business divisions: Cord Blood Bank, Stem Cell Therapy, Health Functional Food, Import and Distribution of Natural Cosmetics and Healthcare Services. The Cord Blood Bank division is involved in collecting and storing stem cells from the newborn's umbilical cord. The Stem Cell Therapy division manufactures allogeneic stem cell drug products. The Health Functional Food division offers vitamins and nutritional supplements. The Import and Distribution of Natural Cosmetics division is involved in the sales and marketing of natural cosmetics imported by Pevonia Inc. The Healthcare Services division provides healthcare solutions such as bizcare, insu-care, affiliate, telehealth services and medical devices through web, mobile, and call centers. The company was founded by Yoon-Sun Yang and Won-Il Oh on June 26, 2000 and is headquartered in Seongnam, South Korea.

Seneca Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Cornell provides education about the earth and atmospheric sciences. They offer summer and winter sessions. Their students contact them through phone and email services.

Jiangsu Dubu Biotechnology Co., Ltd., established on 2021-01-19, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;pharmaceutical production;Drug Wholesale;Drug retail;Inspection and testing service;Import and export agency;Import and export;Technology Import and Export;Food additive production;Health food production;Production of hygiene products and single-use medical products;Cosmetic production;Disinfectant production(Free of Hazardous Chemicals)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Biochemical product technology research and development;Engineering and Technology Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Experimental analysis instrument sales;Research and development of bio-based materials technology;Manufacturing of bio-based materials;Sales of bio-based materials;New material technology research and development;Food Additive Sales;Retailing of Edible Agricultural Products;Cosmetics Retail;Personal Hygiene Sales;Sales of hygiene products and single-use medical products;Chemical product sales(No licensed chemical products);Information Consulting Service(Not including licensing information consulting services);Conference and Exhibition Services;R&D and application of cell technology;Medical Research and Experimental Development;Manufacturing of daily necessities;HR Services(Excludes job brokerage activities,Labor dispatch service);Labor service(Does not include labor dispatch);Business agency service;Personal Business Services(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Apollo Endosurgery develops medical devices for the diagnosis and treatment of gastrointestinal diseases. The company’s device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo’s products include the X-Tack™ Endoscopic HeliX Tacking System, the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon. Apollo Endosurgery was founded upon the initial work of the Apollo Group, an international think tank of world-renowned gastroenterologists and surgeons from five leading universities (Mayo Clinic, Johns Hopkins, Medical University of South Carolina, University of Texas Medical Branch-Galveston and Chinese University-Hong Kong.) Disappointed with the pace of innovation in therapeutic flexible endoscopy, the Group assembled in 1998 (Timeline) with the goal to advance the new discipline; their specific focus was the use of long, flexible instruments deployed through a natural orifice in order to diagnose and potentially treat gastrointestinal disorders.